Isomorphic Labs announced a $5 billion Series C on November 17 to move its first experimental medicines toward human trials, six months after raising $2.1 billion.

Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining and Alphabet investing again. Isomorphic did not disclose a valuation, The Next Web reported.

Led by Demis Hassabis, the London company uses its IsoDDE AI models to help design and refine drug candidates for its own pipeline and pharmaceutical partners, including Eli Lilly, Novartis and Johnson & Johnson. Isomorphic says its cancer and immunology programs have produced positive preclinical results.

Hassabis previously targeted first clinical trials by the end of 2026 but would not give Bloomberg an updated timetable, The Next Web reported. He said regulatory submissions were on track and more announcements would follow in 2027.

Sources
1Isomorphic Labs announces $5 Billion Series C funding ↗
2Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine ↗
3Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design ↗
4Startup.eu: Series C amount explicitly denominated in USD ↗
5Isomorphic Labs secures US$2.1B funding to scale AI drug discovery ↗